AstraZeneca to upgrade US listing in ‘knock-back for London’ | AstraZeneca

Astrazeneca, England’s largest drug producer, said that he would directly list his shares directly on the New York Stock Exchange with a decision defining his shares as a “back to London”.

The FTSE 100 company said that the direct list in New York will replace the trade in American Depositer receipts (ADRS), which allowed us to expose to investors to a non -US company.

While Chancellor Rachel Reeves addressed the Labor Party conference in Liverpool with tensions between government and jobs, the company organized speculation about whether he could translate his list from England to the United States. Such a movement will represent a impact that damages the government’s growth targets.

The second largest listed company in the UK, which has a market value of £ 170.5 billion, insisted that it will remain in Cambridge, England and listed on the London Stock Exchange.

However, the New York list puts US shares equally with the stock listed in London.

Michel Demaré, the chairman of the company, said that the proposed structure will “allow global investors to reach a wider mixture and make all our shareholders have the opportunity to participate in the exciting future of Astrazeneca”.

The movement that the shareholders should approve opens the company to US pension funds.

The US is the world’s largest capital pool and the largest pharmaceutical market. Astrazeneca won $ 23.2 billion (£ 17,25 billion) last year in US revenue, about 43% of its total and the figure is expected to reach 50% at the end of the decade.

Neil Wilson Saxo markets from the investment platform said: “Probably there is no relief in New York because it does not follow a primary list, but the decision is not the approval of London.” He said that the decision was çok a little back for London ”.

Stoker Aj Bell’s investment director Russ Mold said: “Although there is no suggestion that Astrazeneca’s sticks and the primary list will move its primary list from London, there may be a little tension around the risk of losing one of the biggest components of the England market this morning.

“For longer -term moves, it points to the possibility of a more dramatic change at some point in the future, even though there is a direct logic of shifting to a direct list in the United States rather than the American deposit receipts beyond the installation.

“Great investors can ask questions about Astrazeneca’s final intentions before voting for this year’s change.”

The group’s commitment to England was expected to create 1,000 jobs after pause the planned £ 2OOM expansion of the research site in Cambridge at the beginning of this month. In January, he renewed the vaccine area in Speke in Liverpool, renewing £ 450 million and made a deduction with government support after months of negotiations.

In the midst of the government’s ongoing row on drug pricing, it is among a number of projects that have been abandoned or paused by large pharmaceutical companies.

There are also reports that Sir Pascal Soriot, a long -term CEO Sir Pascal Soriot and potentially wants to move the company’s center to the USA.

Soriot clearly expressed his disappointment about the rejection of Astrazeneca’s Breast Cancer Drug Entherdu, and Britain and Europe have fallen behind China and the United States in Resesarch. A recent industrial report showed that Britain has reduced global rankings in investment and research.

Donald Trump increased the pressure on the pharmaceutical industry, threatened to apply upright tariffs unless they invest in the United States, and traditionally asked them to reduce their prices that were much higher in the United States. The deadline for companies to respond is Monday.

A change in the listing of Astrazeneca will be a major loss for the London Stock Exchange, which has undergone a series of departures by companies looking for higher values. In recent years, the equipment rental company Ashtead, Paddy Power bettor owner Flutter Entertainment, Building Materials Supplier CRH and packaging company Smurfite Westrock Lse’den left.

Such a movement of Astrazeneca will probably attempt to intervene by the British government that makes life sciences one of the main growth columns. However, he would not have official power to prevent Astrazeneca from carrying the list.

For several years, Soriot was the highest paid general manager at FTSE 100 and received £ 14.7 million in 2024 and £ 16.85 million in the previous year. Last year, the payment package took place behind the existing and former boss of the engineering group Melrose, Peter Dilnot and Simon Peckham respectively.

The government was approached for a comment.